Results 161 to 170 of about 13,388,853 (301)

Association of GLP‐1 Receptor Agonists With Gastrointestinal and Liver Outcomes in Adults With Type 2 Diabetes: A Target Trial Emulation Study

Diabetes, Obesity and Metabolism, EarlyView.
Dazheng Zhang, Ying Lu, Xinyao Jian, Haoyuan Wang, Jacquelyn Hatch‐Stein, Ronen Stein, Jennifer Panganiban, Yong Chen   +7 more
wiley   +1 more source

DPP-4 Inhibitors

Diabetes Care, 2011
openaire   +2 more sources

Effects of esaxerenone add‐on therapy versus angiotensin II receptor blocker dose escalation on albuminuria and blood pressure in hypertensive patients with type 2 diabetes: An exploratory randomized study

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims Residual albuminuria remains a major clinical challenge in patients with type 2 diabetes mellitus and hypertension despite renin–angiotensin system inhibitor therapy. Esaxerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, reduces albuminuria; however, its effects on oxidative stress remain unclear.
Makoto Ohara, Takemasa Omachi, Nobuaki Takehana, Tomoki Fujikawa, Naoya Osaka, Shunichiro Irie, Michishige Terasaki, Yusaku Mori, Takanori Matsui, Sho‐ichi Yamagishi   +9 more
wiley   +1 more source

Linagliptin, a Selective DPP-4 Inhibitor, Attenuates Ketamine- and Diazepam-Induced Deficits in Passive Avoidance Performance in Mice. [PDF]

Brain Sci
Fronc K, Listos P, Kasprzak P, Berger M, Słowik T, Kotlińska J, Poleszak E, Baranowska-Bosiacka I, Emilia L, Łupina M, Pysiewicz A, Listos J.   +11 more
europepmc   +1 more source

Comparison of DPP-4 Inhibitors

The Journal of Korean Diabetes, 2013
Nam Hoon Kim, Sin Gon Kim
openaire   +1 more source

Role of glucagon in metabolic diseases

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Currently, diabetes is defined as “a chronic hyperglycemic state resulting from the absolute or relative insufficiency of insulin action,” emphasizing its characterization as an insulin‐related disease. However, glucagon dysregulation should also play a critical role in the pathophysiology of type 2 diabetes.
Tadahiro Kitamura, Yoko Tabei, Masaki Kobayashi   +2 more
wiley   +1 more source

Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice. [PDF]

J Diabetes Investig
Kubota-Okamoto S, Kubota S, Tsuchida H, Liu Y, Banno S, Imaizumi T, Fujisawa T, Takahashi Y, Kato T, Horikawa Y, Iizuka K, Murakami T, Fujiwara Y, Kuwata H, Yamazaki Y, Seino Y, Tsunekawa S, Yabe D.   +17 more
europepmc   +1 more source

Temporal distribution of acute kidney injury–related hospitalizations after initiation of sodium–glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single‐center eGFR analysis

Journal of Diabetes Investigation, EarlyView.
Among 190 older adults who experienced AKI‐related hospitalization after SGLT2 inhibitor initiation, 31.1% were hospitalized within 30 days. In an independent single‐center cohort, sustained early eGFR decline was associated with older age and use of one or two triple‐whammy‐related drug classes.
Kazuya Hiura, Ayana Tatsuno, Yamato Noto, Ryosuke Wakamatsu, Masayuki Sakunami, Ryu Kobayashi, Miki Yamashita   +6 more
wiley   +1 more source

Gingival-Dominant Presentation of DPP-4 Inhibitor-Associated Bullous Pemphigoid: A Case Report. [PDF]

Cureus
Fujii Y, Kataoka T, Togashi C, Ishikawa M, Kawase-Koga Y.   +4 more
europepmc   +1 more source

Does DPP-4 inhibitor treatment affect the clinical outcomes of COVID-19 in type 2 diabetes mellitus patients? [PDF]

North Clin Istanb, 2022
Erol RS, Sen EC, Ozturk FY, Sarac Z, Kokoglu GL, Canat MM, Yildiz D, Aytekin YE, Sevgi DY, Altuntas Y.   +9 more
europepmc   +1 more source